ROBOSENSE-LIDAR
RoboSense LiDAR , the leading Smart LiDAR Sensor provider and GAC Aion New Energy Automobile Co., Ltd. (“GAC Aion”) set up by Guangzhou Automobile Group Co., Ltd (GAC Group，6601238.SH，02238.HK) , a Fortune 500 company and one of the automobile groups with the most complete industry chain in China jointly announced that GAC has selected RoboSense's second-generation intelligent solid-state LiDAR equipped with the ADiGO autonomous driving system，and will be mass-produced on a variety of autonomous driving models including the Aion LX of GAC Aion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005558/en/
ADiGO is an intelligent driving ecosystem led by GAC. This independently developed and interconnected ecosystem integrates smart factory, autopilot system, and IoT system. Powered by big data and various AI technologies, the self-driving system is available for mass production in L3 and is able to support L4 pilot running in some closed scenarios. The current ADiGO system on the Aion LX and Aion V uses a triple perception system (camera, millimeter wave radar, high-precision map) to achieve L3 autonomous driving in highway and urban expressway scenes.
The characteristics of Robosense's second-generation LiDAR active high-precision three-dimensional perception allows the ADiGO system to obtain more reliable perception information and ensure driving safety. It adopts a revolutionary two-dimensional MEMS smart chip scanning architecture and has a unique intelligent "GAZE" function, which can adjust the scanning method according to the driving scene, improve the perception of LiDAR, and help improve the performance and experience of autonomous driving. While achieving hardware intelligence verification, RS-LiDAR-Algorithm, the core of software intelligence, has more than 13-years of technology research and development accumulation. During the 5-year commercialization of LiDAR products, it has been verified by more than 100 partners in multiple scenarios around the world. Internally integrated AI perception algorithm, synchronously output 3D point cloud data and target-level environment perception results. The second-generation intelligent solid-state LiDAR helps the ADiGO system achieve a leap from safety to comfort in the driving experience under various road conditions.
In high-speed scenes, intelligent “GAZE” dynamically increases the vertical resolution of the ROI area, allowing the ADiGO system to find distant obstacles earlier, and enhance the autonomous driving experience on highways and urban expressways. In urban scenes, intelligent “GAZE” dynamically improves refresh the frame rate helps the ADiGO system respond more quickly to the dynamic changes of surrounding vehicles，pedestrians and other obstacles.
Due to technological innovation, the second-generation intelligent LiDAR can effectively control hardware costs, allowing more consumers to obtain a safer and more comfortable experience of autonomous driving. In the future, RoboSense will continue to promote technological innovation. Through the sustainable upgrad of intelligent LiDAR product system solution, it will work with partners to promote the intelligent car ecosystem.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world leading provider of Smart LiDAR Sensor Systems. It incorporates LiDAR sensors, AI algorithms and IC chipsets that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to produce outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability superior to humans.
About GAC Motor (https://www.gac-motor.com ):
Guangzhou Automobile Group Co., Ltd. (“GAC”) was incorporated in June 1997. In 2020, GAC’s production and sales both exceeded 2 million, with a positive year-on-year growth. Based on export planning, GAC Group successfully pushed ahead its international business, and GAC MOTOR was born with the right time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005558/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release
Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom